Secondary Logo

Journal Logo

Institutional members access full text with Ovid®


Tam, Emily K. BA*; Golchet, Pamela MD; Yung, Madeline MD*; DeCroos, Francis C. MD; Spirn, Marc MD§; Lehmann-Clarke, Lydia; Ambresin, Aude MD; Tsui, Irena MD**

doi: 10.1097/IAE.0000000000001546
Original Study

Purpose: Anti–vascular endothelial growth factor therapy has improved the prognosis for patients with central retinal vein occlusion (CRVO). However, most studies published to date exclude ischemic CRVO. The purpose of this study was to describe the outcome in eyes with ischemic CRVO treated with anti–vascular endothelial growth factor therapy.

Methods: Thirty-seven patients with ischemic CRVO from 3 centers were followed for at least 6 months. Data on patient demographic, vision status, and anti–vascular endothelial growth factor treatments were collected.

Results: Average number of injections during the study period was 5. Younger age was associated with improved vision (P = 0.006). Patients with improved visual outcomes tended to have macular edema as the primary indication for treatment, whereas patients with worse outcomes tended to have neovascularization as the primary indication for treatment.

Conclusion: This study highlights significant variability in the use of anti–vascular endothelial growth factor therapy for ischemic CRVO and underscores that eyes with neovascularization tend to have worse visual outcomes.

There is no established standard for treatment of ischemic central retinal vein occlusion. The use of anti–vascular endothelial growth factor agents to treat ischemic central retinal vein occlusion is highly variable, and outcomes may depend on age and initial indications for treatment.

*David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California;

Benjamin Eye Institute, Los Angeles, California;

Southeastern Retina Associates, Chattanooga, Tennessee;

§The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania;

Department of Ophthalmology, Medical Retina Unit, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland; and

**Stein Eye Institute, University of California, Los Angeles, Los Angeles, California. Doheny Eye Institute, University of California, Los Angeles, Los Angeles, California.

Reprint requests: Irena Tsui, MD, Jules Stein Eye Institute, University of California, Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095; e-mail:

Stein Eye Institute receives an unrestricted departmental grant from the Research to Present Blindness (RPB) foundation.

Paper presented at American Society of Retina Specialists Annual Meeting, San Francisco, CA, August 9–14, 2016.

None of the authors has any financial/conflicting interests to disclose.

© 2018 by Ophthalmic Communications Society, Inc.